The ready-to-use liquid injectable neuromodulator AI-09 achieved successful results in a phase 1-2 study for the treatment of moderate to severe glabellar wrinkles, Eirion Therapeutics Inc. announced in a press release.
According to the release, the double-blind, placebo-controlled, dose-escalated study evaluated 96 patients’ responses to the injectable. Results were dose-dependent with higher doses yielding more effective and longer-lasting results, including up to 6 months.
The company also surveyed more than 800 U.S. subjects who have been treated in the past with a neuromodulator for their glabellar lines, asking participants if results that lasted 6 months would be preferred.
Almost all participants (97%) stated that it would be better for them and 63% said it would be “a lot better” or “amazingly better.” When looking solely at the women’s responses, the researchers observed that 73% of women reported 6-month-long results would be “a lot” or “amazingly” better.
“We were excited by both the clinical trial and survey results demonstrating that AI-09 could be an attractive treatment solution for patients and physicians,” Jon Edelson, MD, CEO and president of Eirion, said in the release. “With these AI-09 clinical trial results, Eirion continues to advance its pipeline of innovative aesthetic medical product candidates.”
